Titan Biotech Limited has scheduled a board meeting for September 3, 2026, to consider the proposal for issuing bonus shares and finalize details for its 34th Annual General Meeting. The trading window for designated persons remains closed until 48 hours after the outcome is declared.

The meeting will be held at the company’s office in New Delhi. Directors are expected to approve the draft notice for the AGM and the director’s report for the fiscal year ended March 31, 2026. They will also determine the book closure dates and record dates for shareholder voting.

Agenda Highlights

The board agenda includes several key corporate governance items:

• Consider and approve the proposal for issue of bonus shares, subject to requisite approvals
• Finalize time, date, and venue for the 34th Annual General Meeting
• Approve draft Notice of AGM and draft Director’s Report with annexures for FY26
• Finalize dates for book closure, record date, and e-voting matters

Trading Window Closure

In accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities by designated persons closed on August 31, 2026. It will remain closed until 48 hours after the declaration of the board meeting outcome on September 3, 2026.

Titan Biotech reported a significant improvement in profitability for the first quarter of FY26, with standalone net profit rising 53% year-on-year to ₹94.6 crore. The growth was supported by a 29% increase in revenue, which reached ₹609.8 crore compared to ₹472.2 crore in the corresponding period last year. Consolidated net profit also expanded by 58% to ₹108.6 crore, up from ₹68.6 crore in Q1FY25.

The company’s operating performance strengthened alongside top-line growth. Standalone earnings before tax (EBT) climbed to ₹127.3 crore from ₹81.1 crore, reflecting an expansion in operating leverage. The Board of Directors approved the unaudited financial results at its meeting held on August 13, 2026. The results have been reviewed by the Audit Committee and subjected to a limited review by the statutory auditors as per SEBI regulations.

Financial Highlights

Consolidated Performance

On a consolidated basis, total income from operations stood at ₹609.8 crore, identical to the standalone figure. Consolidated net profit after tax was ₹108.6 crore, compared to ₹68.6 crore in the prior year period. Basic earnings per share for the consolidated entity were ₹2.63, up from ₹8.30 in Q1FY25, though the face value difference (₹10 vs ₹2 in prior reporting) requires careful comparison. The paid-up equity share capital remained unchanged at ₹82.6 crore.

What the Numbers Show

The divergence between revenue growth (29%) and earnings before tax growth (57%) indicates improved operational efficiency during the quarter. The expansion in pre-tax profits suggests that cost controls or product mix shifts allowed the company to retain more earnings per unit of sales than in the previous year. This operational improvement translated directly to the bottom line, where both standalone and consolidated net profits outpaced revenue growth significantly. The company noted that freight amounts were added to revenue from operations and neutralized in total other expenses, ensuring no distortion in sales figures.